Study Reveals Frequent Stop-and-Start Patterns with GLP-1 Drugs

Why It Matters

Inconsistent GLP‑1 use undermines the drugs’ cardiovascular and renal benefits, highlighting a need for targeted adherence support across vulnerable populations.

Key Takeaways

• 40% stop GLP‑1 meds within first year.
• 60% discontinue GLP‑1 use by two years.
• More than half who stop restart within a year.
• Medicaid, Medicare, and Black patients show higher discontinuation.

Pulse Analysis

The study underscores a persistent adherence gap in GLP‑1 therapies, which have become cornerstone treatments for type 2 diabetes and obesity. While clinical trials demonstrate robust reductions in heart attack risk, kidney disease progression, and weight, real‑world data reveal that a sizable portion of patients interrupt therapy, often due to side effects like nausea or cost barriers tied to public insurance. Understanding these patterns is crucial for clinicians aiming to maximize therapeutic outcomes.

Provider type and medication choice emerged as powerful levers for retention. Patients whose initial prescription came from an endocrinologist were 10% less likely to discontinue, suggesting that specialist expertise and counseling may mitigate concerns early on. Moreover, newer agents such as tirzepatide and semaglutide showed 41% and 28% lower discontinuation rates respectively, likely reflecting improved efficacy, tolerability, or patient perception. Payers and health systems can leverage these insights to prioritize formulary placement and patient education for high‑risk groups.

From a policy perspective, the findings call for interventions that address socioeconomic disparities. Tailored adherence programs, side‑effect management protocols, and insurance designs that reduce out‑of‑pocket costs could curb the stop‑and‑start cycle. As GLP‑1 drugs expand into broader cardiovascular prevention strategies, ensuring sustained use will be pivotal for translating clinical benefits into population‑level health gains.